June 26
DOHA, Qatar, June 26, 2011 -
From Egypt to Syria, the Arab Spring
has ushered in a new era of enquiry, freedom of expression and
debate in the Middle East.
MUNICH, June 26, 2010 - Results from the ADVANCE study presented in a late breaking clinical
trial session at the ERA-EDTA 2010 Congress provide new insights into the
management of secondary hyperparathyroidism (SHPT) in chronic kidney disease
(CKD) patients.
ORLANDO, Florida, June 26, 2010 - Bristol-Myers Squibb Company (NYSE: BMY)
and AstraZeneca (NYSE: AZN) today announced results up to 76-weeks from a
Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy
with metformin, which produced long-term glycemic improvement [as measured
by glycosylated hemoglobin level (HbA1c)] in treatment-naive adults with
type 2 diabetes mellitus inadequately controlled on diet and exercise
compared to treatment with an investigational 10 mg dose of saxagliptin or
metformin alone.
ORLANDO, Florida, June 26, 2010 - Bristol-Myers Squibb Company (NYSE: BMY)
and AstraZeneca (NYSE: AZN) today announced results from a 52-week Phase 3b
study in adults with type 2 diabetes who had inadequate glycemic control on
metformin therapy plus diet and exercise.
ORLANDO, Florida, June 26, 2010 - Results from a 24-week Phase 3 clinical
study demonstrated that the addition of the investigational drug
dapagliflozin achieved reductions in the primary endpoint, glycosylated
hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes patients
who were treated with insulin (with or without oral anti-diabetes medications
(OADs)), compared to placebo plus insulin (with or without OADs).
